• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CDK4/6抑制剂在乳腺癌患者治疗中的应用：多学科圆桌讨论总结

CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion.

作者信息

Preusser Matthias, De Mattos-Arruda Leticia, Thill Marc, Criscitiello Carmen, Bartsch Rupert, Ruhstaller Thomas, de Azambuja Evandro, Zielinski Christoph C

机构信息

Clinical Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria; Comprehensive Cancer Centre, Medical University Vienna - General Hospital, Vienna, Austria.

Vall d'Hebron Institute of Oncology, Barcelona, Spain.

出版信息

ESMO Open. 2018 Aug 20;3(5):e000368. doi: 10.1136/esmoopen-2018-000368. eCollection 2018.

DOI:10.1136/esmoopen-2018-000368
PMID:30167331
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6109817/
Abstract

This article is the result of a round-table discussion organised by ESMO Open in Vienna in December 2017. Its purpose is to discuss the background and advances in the evidence regarding cyclin-dependent kinase 4/6 inhibitors (palbociclib, ribociclib and abemaciclib) in the treatment of metastatic and early-stage breast cancer and to explore what the key open research questions are and next steps should be.

摘要

本文是欧洲肿瘤内科学会（ESMO）开放杂志于2017年12月在维也纳组织的一次圆桌讨论的成果。其目的是探讨细胞周期蛋白依赖性激酶4/6抑制剂（帕博西尼、瑞博西尼和阿贝西利）在治疗转移性和早期乳腺癌方面的证据背景与进展，并探究关键的待解决研究问题以及后续步骤应该是什么。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1708/6109817/fdb3e39c1d64/esmoopen-2018-000368f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1708/6109817/65455b7bab4c/esmoopen-2018-000368f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1708/6109817/fdb3e39c1d64/esmoopen-2018-000368f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1708/6109817/65455b7bab4c/esmoopen-2018-000368f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1708/6109817/fdb3e39c1d64/esmoopen-2018-000368f02.jpg

相似文献

1
CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion.CDK4/6抑制剂在乳腺癌患者治疗中的应用：多学科圆桌讨论总结
ESMO Open. 2018 Aug 20;3(5):e000368. doi: 10.1136/esmoopen-2018-000368. eCollection 2018.
2
Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.比较不同细胞周期蛋白依赖性激酶 4/6 抑制剂在转移性乳腺癌中的治疗相关不良事件：一项网络荟萃分析。
Cancer Treat Rev. 2020 Nov;90:102086. doi: 10.1016/j.ctrv.2020.102086. Epub 2020 Aug 17.
3
A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.用于治疗转移性乳腺癌的细胞周期蛋白依赖性激酶抑制剂的最新全面综述。
Curr Med Res Opin. 2017 Sep;33(9):1559-1569. doi: 10.1080/03007995.2017.1348344. Epub 2017 Jul 25.
4
CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an pro and con discussion.CDK4/6 抑制在低负荷和广泛转移性乳腺癌中的应用：赞成和反对观点综述。
ESMO Open. 2019 Nov 13;4(6):e000565. doi: 10.1136/esmoopen-2019-000565. eCollection 2019.
5
Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.细胞周期蛋白依赖性激酶 4/6 抑制剂在乳腺癌中的应用：帕博西尼、瑞博西尼和阿贝西利。
Breast Cancer Res Treat. 2017 Nov;166(1):41-54. doi: 10.1007/s10549-017-4385-3. Epub 2017 Jul 24.
6
Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.乳腺癌中环磷酰胺依赖性激酶 4/6 抑制剂相关毒性和药物相互作用的临床处理：实用注意事项和建议。
Oncologist. 2017 Sep;22(9):1039-1048. doi: 10.1634/theoncologist.2017-0142. Epub 2017 Jul 13.
7
Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.细胞周期蛋白依赖性激酶 4/6 抑制剂在女性晚期或转移性乳腺癌中的应用。
Am J Health Syst Pharm. 2019 Aug 1;76(16):1183-1202. doi: 10.1093/ajhp/zxz121.
8
CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.CDK4/6 抑制剂拓展乳腺癌治疗选择：哌柏西利、瑞博西利和阿贝西利。
BioDrugs. 2019 Apr;33(2):125-135. doi: 10.1007/s40259-019-00337-6.
9
CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.CDK4/6 抑制作为乳腺癌的治疗策略：帕博西利、瑞博西利和阿贝西利。
Semin Oncol. 2017 Dec;44(6):395-403. doi: 10.1053/j.seminoncol.2018.03.006. Epub 2018 Mar 26.
10
Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.细胞周期蛋白依赖性激酶4/6抑制剂在当前及未来癌症治疗时代的作用
J Oncol Pharm Pract. 2019 Jan;25(1):110-129. doi: 10.1177/1078155218770904. Epub 2018 May 4.

引用本文的文献

1
Insulin-like growth factor 2 as a driving force for exponential expansion and differentiation of the neonatal thymus.胰岛素样生长因子2作为新生儿胸腺指数性扩张和分化的驱动力。
Development. 2025 Apr 1;152(7). doi: 10.1242/dev.204347. Epub 2025 Apr 10.
2
Real-world study of patients with HR+/ HER2- metastatic breast cancer treated with palbociclib and fulvestrant.哌柏西利与氟维司群治疗激素受体阳性/人表皮生长因子受体2阴性转移性乳腺癌患者的真实世界研究
Future Oncol. 2025 Jan;21(1):83-94. doi: 10.1080/14796694.2024.2442302. Epub 2025 Jan 15.
3
Therapeutic Prospects of Abemaciclib for Patients with Endometrial Cancer.

本文引用的文献

1
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.MONARCH 3：阿贝西利作为晚期乳腺癌初始治疗。
J Clin Oncol. 2017 Nov 10;35(32):3638-3646. doi: 10.1200/JCO.2017.75.6155. Epub 2017 Oct 2.
2
CDK4/6 inhibition triggers anti-tumour immunity.细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制可触发抗肿瘤免疫。
Nature. 2017 Aug 24;548(7668):471-475. doi: 10.1038/nature23465. Epub 2017 Aug 16.
3
Predicting treatment resistance and relapse through circulating DNA.通过循环 DNA 预测治疗抵抗和复发。
阿贝西利治疗子宫内膜癌的前景。
Curr Oncol. 2024 Sep 12;31(9):5374-5383. doi: 10.3390/curroncol31090397.
4
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.阿贝西利单药或联合内分泌治疗晚期乳腺癌患者循环肿瘤 DNA 中基线和获得性基因组改变的图谱。
Clin Cancer Res. 2024 May 15;30(10):2233-2244. doi: 10.1158/1078-0432.CCR-22-3573.
5
Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer.放射组学可预测激素受体阳性转移性乳腺癌对CDK4/6抑制剂的早期反应。
NPJ Breast Cancer. 2023 Aug 11;9(1):67. doi: 10.1038/s41523-023-00574-7.
6
Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers.阿贝西利在帕博西尼耐药的激素受体阳性转移性乳腺癌中有效。
Cancer Res. 2023 Oct 2;83(19):3264-3283. doi: 10.1158/0008-5472.CAN-23-0705.
7
Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models.针对 mTOR 克服 ER 阳性乳腺癌模型中对激素和 CDK4/6 抑制剂的耐药性。
Sci Rep. 2023 Feb 15;13(1):2710. doi: 10.1038/s41598-023-29425-y.
8
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer.同时靶向细胞周期蛋白依赖性激酶2（CDK2）和细胞周期蛋白依赖性激酶4/6（CDK4/6）可克服雌激素受体阳性（ER+）乳腺癌对芳香化酶抑制剂和CDK4/6抑制剂的耐药性。
NPJ Precis Oncol. 2022 Sep 24;6(1):68. doi: 10.1038/s41698-022-00311-6.
9
Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem.乳腺癌中拉帕替尼靶向抗HER2/ErbB2治疗耐药：攻克难题的机遇
Cancer Drug Resist. 2020 Feb 28;3(2):179-198. doi: 10.20517/cdr.2019.92. eCollection 2020.
10
Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study.在二线治疗中，与单纯内分泌治疗相比，哌柏西利联合内分泌治疗显著提高了激素受体阳性/人表皮生长因子受体2阴性转移性乳腺癌患者的总生存期：一项大型机构研究。
Int J Cancer. 2022 Jun 15;150(12):2025-2037. doi: 10.1002/ijc.33959. Epub 2022 Mar 3.
Breast. 2017 Aug;34 Suppl 1:S31-S35. doi: 10.1016/j.breast.2017.06.024. Epub 2017 Jul 8.
4
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer.单细胞动力学决定三阴性乳腺癌对 CDK4/6 抑制的反应。
Clin Cancer Res. 2017 Sep 15;23(18):5561-5572. doi: 10.1158/1078-0432.CCR-17-0369. Epub 2017 Jun 12.
5
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.MONARCH 2 研究：阿贝西利联合氟维司群治疗 HR+/HER2-晚期乳腺癌患者的疗效，这些患者在接受内分泌治疗时发生了进展。
J Clin Oncol. 2017 Sep 1;35(25):2875-2884. doi: 10.1200/JCO.2017.73.7585. Epub 2017 Jun 3.
6
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).第三届欧洲中学教育（ESO）-欧洲肿瘤内科学会（ESMO）晚期乳腺癌国际共识指南（ABC 3）
Ann Oncol. 2017 Dec 1;28(12):3111. doi: 10.1093/annonc/mdx036.
7
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.NeoPalAna研究：新辅助哌柏西利（一种细胞周期蛋白依赖性激酶4/6抑制剂）联合阿那曲唑治疗临床2期或3期雌激素受体阳性乳腺癌
Clin Cancer Res. 2017 Aug 1;23(15):4055-4065. doi: 10.1158/1078-0432.CCR-16-3206. Epub 2017 Mar 7.
8
Palbociclib and Letrozole in Advanced Breast Cancer.帕博西尼联合来曲唑治疗晚期乳腺癌。
N Engl J Med. 2016 Nov 17;375(20):1925-1936. doi: 10.1056/NEJMoa1607303.
9
Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor.芳香化酶抑制剂治疗后疾病进展的转移性乳腺癌患者中ESR1循环突变的动力学、预后及预测价值
Oncotarget. 2016 Nov 15;7(46):74448-74459. doi: 10.18632/oncotarget.12950.
10
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.瑞博西尼作为激素受体阳性晚期乳腺癌的一线治疗方案
N Engl J Med. 2016 Nov 3;375(18):1738-1748. doi: 10.1056/NEJMoa1609709. Epub 2016 Oct 7.